Related Experiment Video
Updated: May 2, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Two case reports of MDA5-type seronegative dermatomyositis.
Lauren C Balogh1, Airiss R Chan2, Elaine A Yacyshyn3
1Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
This study details two rare cases of amyopathic MDA5-dermatomyositis without detectable myositis-specific autoantibodies. It explores reasons for seronegative results in dermatomyositis, aiding diagnosis and understanding of this autoimmune condition.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Dermatomyositis (DM) is an autoimmune inflammatory myopathy characterized by skin and muscle inflammation.
- Myositis-specific autoantibodies (MSAs) are crucial for classifying DM subtypes and predicting patient prognosis.
- Certain DM presentations, like amyopathic MDA5-DM, can occur without detectable MSAs.
Observation:
- Two patients presented with classic amyopathic MDA5-dermatomyositis clinical features, including photosensitive dermatitis, heliotrope rash, Gottron's papules, and nailfold changes.
- Despite characteristic symptoms, standard autoimmune serological testing for MSAs yielded negative results in both cases.
- This highlights an unusual subset of DM patients who do not present with expected autoantibody profiles.
Findings:
- The study describes two unconventional cases of seronegative amyopathic MDA5-DM.
- Potential explanations for the absence of detectable MSAs include fluctuating antibody levels, alternative non-MSA related pathophysiological mechanisms, or limitations in current diagnostic immunoassays.
- These findings challenge the conventional reliance on MSAs for diagnosing and subtyping all DM cases.
Implications:
- The findings suggest a need for broader diagnostic considerations in suspected DM cases, especially when serological tests are negative.
- Further research into non-MSA driven DM and improved immunoassay sensitivity is warranted.
- Understanding these seronegative cases can improve diagnostic accuracy and patient management for rare autoimmune myopathies.
More Related Videos
10:05Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
Published on: January 17, 2018
05:55Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myocarditis II: Clinical Features and Diagnostic Tests